The Suzuki-Miyaura derivatisation of free amino acids, peptides and proteins is an attractive area with much potential utility for medicinal chemistry and chemical biology. Here we report the modification of unprotected and Boc-protected aromatic amino acids and dipeptides in aqueous media, enabling heteroarylation and vinylation. We systematically investigate the impact of the peptide backbone and adjacent amino acid residues upon the reaction. Our studies reveal that whilst asparagine and histidine hinder the reaction, by utilising dppf, a ferrocene-based bidentate phosphine ligand, cross-coupling of halophenylalanine or halotryptophan adjacent to such a residue could be enabled. Our studies reveal dppf to have good compatibility with all unprotected, proteinogenic amino acid side chains.
Introduction
Since the discovery of palladium's catalytic potential, numerous reactions have been developed for the formation of carboncarbon and carbon-heteroatom bonds. [1] Through the development of the Suzuki-Miyaura reaction, organoboron compounds were introduced as versatile coupling partners.
[2]
The use of boron as an organometallic partner provides several advantages such as its environmentally benign nature, commercial availability, high functional group tolerance and a compatibility with aqueous conditions.
[3] The Suzuki-Miyaura reaction is therefore often the method of choice for the derivatisation of challenging substrates. It has been utilised for the derivatisation of biomolecules such as nucleosides, [4] amino acids, [5] peptides, [6] but also more complex natural products, [7] and proteins. [5c-d, 8] Site-selective derivatisation of peptides and proteins by bioorthogonal reactions [9] has received great attention as a key component of the chemical biology toolbox and for the labeling of bioactive products.
[8c-d, 10] Additionally, one can explore structure-activity relationships for these biological substrates via the synthesis of related structures, enabled by the presence of a "derivatisation handle" in the amino acid sequence. Introducing halogens onto the side chains of phenylalanine and tryptophan, [11] for example, opens opportunities for latestage peptide functionalisation via palladium-catalysed crosscoupling reactions. Ideally, performing these derivatisations in a late stage of the synthetic pathway would provide a convergent method for rapid screening of structurally related compounds. However, when (partially) unprotected peptide substrates have to be derivatised, the envisaged Pd-catalysed reactions require aqueous conditions to mimic the natural environment of these biomolecules. To find catalytic systems that are compatible with water, various alterations to commonly used reaction conditions in organic solvents have been reported. [12] Unfortunately, when aiming at more complex substrates, (super)stoichiometric amounts of catalyst and ligand are often required. [5d,13] Clearly, catalytic amounts are preferred in view of the associated price of the Pd source and ligand used and in order to avoid large amounts of residual Pd to be scavenged after the reaction. [14] Herein, to address this issue, a compatibility study between Suzuki-Miyaura derivatisation and amino acid main and side chain functionalities was carried out via a systematic screening. By synthesis of dipeptide substrates containing a halogenated phenylalanine, the compatibility of various side chain functionalities could be screened. In this way, each side chain can be investigated individually, ultimately leading to a tool to make predictions for more complex substrates, i.e. polypeptides.
Results and Discussion

Evaluation of various Pd/Ligand systems on 4-bromophenylalanine as a model substrate
To achieve the required compatibility with aqueous conditions, an adaptation of the catalytic species is mandatory. Several examples of water soluble ligands have been reported. We screened complexes of 2-aminopyrimidine-4,6-diol disodium salt (Na2ADHP, 1a) [5d, 15] , 2-(dimethylamino)pyrimidine-4,6-diol disodium salt (Na2ADHP(Me2), 1b) [8d, 14a] , 3,3′,3″-phosphanetriyltris(benzene sulfonic acid) trisodium salt (TPPTS, 2) [4e, 5a] , and sodium 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl-3'-sulfonate (sulfonated SPhos, 3) [3c, 7a] . Beside precatalysts based on these ligands, we also evaluated PdCl2dppf
([1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride) (5a).
[16a] This complex is considered to be insoluble in water, but has been used in aqueous media for the preparation of various biphenyls.
[16b]
Additionally, a biphenylamino-based Pd precatalyst featuring this ligand (5b) was also tested [17] as well as ligandless Pd salts (4a,b).
[8d, 18] Figure 1. Various palladium(-ligand) sources tested during the initial screening with 4-bromophenylalanine.
A screening of these precatalysts was first performed on the model substrate 4-bromophenylalanine (6a) in a reaction with phenylboronic acid. Furthermore, in view of eventual SAR studies regioisomers, 3-(6b) and 2-bromophenylalanine (6c) were also evaluated in the Suzuki-Miyaura reactions with phenylboronic acid. In pure water, the most promising results were obtained with precatalysts 1b (entry 2) and 2 (entry 3). While incomplete conversion to the desired product was observed with 5a in purely aqueous conditions (entry 7), changing to a mixed solvent system significantly improved the reaction outcome. Isopropanol (iPrOH) was selected as a green alternative [19] (entry 8 and 9) to more traditionally used organic solvents that are commonly applied in Suzuki-Miyaura transformations, such as toluene and DMF. No beneficial effect was found upon use of dppf based precatalyst 5b (entry 10). The 2-bromo regioisomer 6c (entry 12) required a longer reaction time to reach a high conversion, while the 3-bromo regioisomer 6b (entry 11) converted at an intermediate rate. These derivatisations are highly interesting since ortho-and meta halogenated regioisomers are generally not considered in the derivatisation of halophenylalanine substrates. [20] The use of 5a is, to the best of our knowledge, hitherto limited to the derivatisation of protected (4-pinacolylborono)phenylalanine (BPA) with aromatic halides and triflates [16a] and has only been applied in aqueous conditions for the preparation of simple biphenyls.
We therefore investigated the scope on unprotected and Boc-protected substrates, that can be directly applied in solid-phase peptide synthesis (SPPS). First, an optimisation of the iPrOH/water ratio was performed (Table 2 ). It was shown that for an unprotected substrate (6a), 50% iPrOH provided the highest conversion (entry 6) using 1 mol% of 5a. To achieve short cross-coupling reaction times (4 h), 5 mol% of 5a was required for complete conversion of 6a (entry 6 vs Table 1, entry 9). On the tertbutyloxycarbonyl (Boc) protected substrate 8a, nearly complete conversion can be reached with as little as 1 mol% of 5a in a limited reaction time (2 h), while the amount of iPrOH required can be <5% (entry 2). As could be expected protected systems gave faster reaction but protection is interestingly not required. Avoiding these main chain protecting groups is a first step in the envisaged derivatisation of more complex peptide substrates in aqueous environment. Boronic acid scope using the PdCl2(dppf) (5a) catalytic system
Next the boronic acid scope was investigated with the optimised reaction conditions identified for reaction of 6a and 8a with phenylboronic acid using precatalyst 5a. Gratifyingly, various (hetero)aromatic boronic acids (Table 3 , entry 1-7) can be introduced on the halogenated phenylalanine substrates 6a and 8a, seemingly independent of the boronic acid. Although the reaction time was set at 2 hours during the initial solvent optimalisation experiments, complete conversion of 8a was reached after only 1 hour at 80°C. Purification of the N-terminally unprotected cross-coupled products (7a, d-j) was performed by preparative HPLC, delivering lower yields characteristic for HPLC purification. Higher isolated yields were obtained for all protected products (9a-h) due to an easier isolation with flash chromatography. Boc protected 4-bromophenylalanine generally reacted faster with boronic acids as was also observed in the model cross-coupling with phenylboronic acid (Table 2) . Next, 9-fluorenylmethyloxy-carbonyl protection (Fmoc) was also evaluated. On Fmoc-4-bromophenylalanine altered reaction conditions are required to avoid removal of the base-labile Fmoc-group observed at 80°C. Although, reaction at a lower temperature (40°C) under otherwise standard reaction conditions showed promising results, HPLC conversion only reached 80% after 24h (see supporting information). In addition to (hetero)aromatic boronic acids, we investigated several non-aromatic boronic acids (Table 3) . Whereas little success was obtained for aliphatic boronic acids, a vinylic substituent can be efficiently introduced, as exemplified by the use of potassium vinyltrifluoroborate as reagent. We opted for this trifluoroborate as a convenient alternative to vinyl boronic acid, [21a] which is reported to readily undergo polymerisation.
[2h, 21b] These potassium trifluoroborates can be used as benchstable alternatives to their respective boronic acids.
[2c] During cross-coupling in aqueous conditions, these trifluoroborates hydrolyse readily to the corresponding boronic acid. [22] To Table 3 . Suzuki-Miyaura reaction on unprotected (6a), Boc-protected 4-bromophenylalanine (8a), unprotected (10a), and Boc-protected 4-iodophenylalanine (11a-c).
achieve high conversions in an acceptable reaction time, 4-iodophenylalanine (10a) needed to be employed as the substrate (Table 3, entry 8 vs 9) . Interestingly, the vinyl group permits a broad scope of further derivatisations, potentially allowing to obtain a variety of hitherto unknown functionalised Phe analogues. In addition to the preparation of N-Boc-4-vinylphenylalanine (9h), it was possible to perform the vinylation on the meta-and ortho-halogenated regioisomers (11b,c) as well, and with similar reactivities (entry 10 and 11). The preparation of protected vinylphenylalanine has primarily been described in organic solvents with vinylstannanes, [23] which suffer from several drawbacks such as poor atom-economy, toxicity and poor solubility in mixed aqueous conditions.
[21a] To the best of our knowledge, this is the first reported vinylation reaction with trifluoroborates on (unprotected) halogenated aromatic amino acids that can be performed in mixed aqueous conditions. Only use of substituted alkenyl boronic acids has previously been reported by Davis and coworkers with 1a on a protected iodinated tyrosine and a protein complex.
[5d]
Evaluation of dipeptide substrates for Suzuki-Miyaura reactions
In order to determine the applicability of the catalytic systems ( Figure 1 ) on increasingly difficult substrates, an explorative study on a slightly more elaborate substrate, H-Gly-Phe(4-Br)-OH (12a), was initially carried out (for experimental data, see supporting information). Similar to the results on halogenated phenylalanine substrates 6, precatalysts 1a, 1b and 2 gave desirable conversions (>95%, see supporting information) in a limited amount of time (2 h) in water with only 5 mol% of catalyst. However, in this case 2.5 equivalents of boronic acid were required to achieve high conversion. While 5a gave correspondingly high conversions in a mixed solvent (H2O/iPrOH 1:1), the [Na2(ADHP)]2Pd(OAc)2 (1a) system was selected as a convenient catalyst to perform a scope study on dipeptides 12 featuring side chain functionality ( As can be seen in Table 4 , most amino acid side chains (aliphatic, aromatic, acidic and basic) do not interfere and readily allow cross-coupling reaction. The thioether functionality of Met (12k) is remarkable in this respect as sulphur is known to poison Pd 0 . [5d, 24] However, for Asn (12j) and His (12l), containing a primary amide and imidazole moiety, respectively, no conversion was observed even after prolonged reaction times (Table 4 , entry 10 and 12). A further evaluation of these substrates was performed by looking specifically at individual functionalities in the protected dipeptide substrates.
Synthesis of derivatised dipeptides with asparagine (Asn) and histidine (His)
To allow cross-coupling with 12j and 12l both dipeptides were prepared as their N-and C-terminal protected derivatives. First, Boc-Asn-Phe(4-Br)-OMe (14a) was investigated as a substrate and subjected to various reaction conditions (Table 5) . We observed that only with PdCl2(dppf) (5a) a high conversion was obtained (Table 5 , entry 6), although only the hydrolysed product 17b was observed by HPLC analysis. Therefore the isolated yield could not be determined. In order to verify whether this smooth conversion could also be realised on partially deprotected dipeptides, a saponification was first carried out (Scheme 1). Since deprotection by hydrolysis in basic conditions led to aspartimide formation and resulted in a mixture of both the carboxylic acid (15) and primary amide side chain (14b), addition of formic acid (1.4 eq, 0.2 eq with respect to LiOH) was mandatory to avoid this side reaction. [25] Scheme 1. Aspartimide formation occurring during basic hydrolysis of 14a, giving rise to a mixture (85:15) of side chain amide (14b) and carboxylic acid. In fact, this aspartimide formation also occurred during the Suzuki-Miyaura derivatisation of 14b (Table 5 , entry 7) and fully deprotected dipeptide 12j, yielding a 1:1 mixture of the carboxylic acid and primary amide in the side chain. Also here, a small amount of formic acid (0.2 eq with respect to K2CO3) solved the problem (entry 8 and 9). [25] This optimised procedure was then repeated with unprotected glutamine dipeptide 12n (entry 10), yielding H-Gln-Phe(4-phenyl)-OH 13n. As observed for amino acids, the lower isolated yields of the dipeptides can be explained by the necessity of purification by preparative HPLC. In analogy to Asn, a stepwise deprotection was followed for histidine (Table 6 ). Dipeptide 18a, featuring a benzyloxymethyl (BOM) protection on the Nπ-position and methyl ester, was selected as BOM protecting allows selective N-Boc-removal by acidolysis. Similarly, whereas other catalytic systems fail to give conversion, PdCl2(dppf) (5a) provided high conversion in a limited time (Table 6 , entry 4). A concomitant hydrolysis of the methyl ester was however also observed in this case, and therefore no isolated yield was determined. The Suzuki-Miyaura derivatisation of partially deprotected 18b (Table 6 , entry 5) and 18c (entry 6, unprotected main chain, imidazole protection was retained) was possible within 4h. To avoid the need for a side chain protecting group on histidine, complexation of the imidazole with several metal halides was investigated (e.g. MgCl2, ZnCl2, NiCl2). After all, addition of 0.1 equivalent of unprotected L-His to the successful reaction of 4-bromophenylalanine and phenylboronic acid (Table 1 , entry 9) nearly completely blocked the reaction pointing to catalyst inhibition through imidazole coordination (see supporting information). These metal halides are potentially capable of coordinating with the interfering functionality and make it less available for disrupting the desired catalysis on peptide substrates such as 12l. [13b, 26] Inhibition of typical Suzuki-Miyaura reactions by the presence of nitrogen-rich heterocycles, such as imidazole, has been reported in non-peptide systems.
[27] Unfortunately, when sacrificial metals were present in the reaction mixture, no improvement was observed. Interestingly, significant amounts (up to 1 eq) of Boc-His-OMe could be added to the standard reaction (Table 1 , entry 9) with retention of acceptable reaction progress (see supporting information). It therefore seems that it is the combination of an unprotected -nitrogen and imidazole ring which blocks the catalysis. Subsequently, we turned towards the corresponding iodinated dipeptide substrate H-His-Phe(4-I)-OH (19a, Table 6 , entry 7). Interestingly, upon use of this substrate it was possible to derivatise the fully deprotected dipeptide, albeit with a limited conversion and yield. To evaluate the effect of the free N  -amine of His in combination with the imidazole moiety, the N-terminal amine was acetylated (19b). As expected, acylation of the Nterminus led to higher conversion (Table 6 , entry 8). A similar trend was observed for tripeptide H-Gly-His-Phe(4-I)-OH (19c) and the acylated equivalent (19d) ( Table 6 , entry 9-10). These results further indicated that an unprotected N  -amine in combination with the unprotected imidazole of His is problematic for Suzuki-Miyaura reaction.
To check whether this dipeptide moiety is also problematic in longer peptide sequences, an earlier reported His-containing heptapeptide 21 [6a] was derivatised using PdCl2(dppf) (5a) precatalyst (Scheme 2). Via use of 5 mol% of 2, Barluenga and co-workers were able to achieve a HPLC conversion of 15-24% after 24 hours (depending on the boronic acid selected). [8a] Gratifyingly, using 5a this unprotected peptide was functionalised with 50% conversion after 2 hours to 22. Increased reaction times did, unfortunately, not further improve the conversion. This incomplete conversion is consistent with the results obtained for the unprotected His-Phe(4-I) containing dipeptides (19a,b) and tripeptides (19c,d) where no full conversion can be achieved (Table 6 ). This result shows that the imidazole moiety remains a troublesome functionality for palladium catalysed reactions, even upon elongation of the peptide substrates.
Scheme 2. Derivatisation of heptapeptide 21, containing histidine and 4-iodophenylalanine using 5a as precatalyst.
In addition to side chain primary amides, we verified whether Cterminal amides could also be used as substrates in the palladium-catalysed cross-coupling reactions (Table 7) . With the classical catalyst systems (1a, 1b, 2 or 4a) we did not find any reaction product. This is all in line with the obtained results for Asn and Gln. However, by means of the ferrocene-based PdCl2(dppf) (5a), conversion of H-Ser-Phe(4-X)-NH2 (23a or 24a) was only possible when the halogen moiety was iodine (entry 6). Excellent conversions were also observed with Leu, Tyr and Ala as the second amino acid component (entry 7-9). The brominated substrates (23a-d, entries 1-3) yielded side products only, whilst microwave heating did not improve the reaction outcome (entry 4 and 5). [28] Entry Substrate Conditions Conv. (%) [a,b] , 
Evaluation of unprotected halotryptophan as substrates in Suzuki-Miyaura reactions.
In order to verify whether another aromatic core would present a similar reactivity, we evaluated brominated tryptophans that were readily available via a biotransformation protocol, [11a] and dipeptides containing this moiety as substrates (Table 8) .
Halotryptophans were previously investigated as substrates for Suzuki-Miyaura reaction. [5a,7a] In this work, various precatalysts on unprotected 5-bromotryptophan (26a) and selected tryptophan dipeptides were evaluated. High conversions on the unprotected dipeptides were obtained with the [Na2ADHP]2Pd(OAc)2 precatalyst 1a (Table 8 , entry 1). In this case the PdCl2(dppf) precatalyst 5a however did not give rise to high conversions (Table 8 , entry 6). In order to achieve By using 1a as a catalyst, it is now possible to isolate derivatised tryptophan dipeptides without protecting groups (29a-c). Furthermore, we verified whether this precatalyst was also able to perform the cross-coupling on other regioisomers of bromotryptophan (Table 9 ). Therefore, we tested 6-bromo-(26b) and 7-bromotryptophan (26c) and gratifyingly good conversions could be achieved (Table 9 , entries 1 and 2). Access to 7-iodotryptophan (30) [11a]
enabled the preparation of 7-vinyltryptophan (31), which in turn permits further derivatisation via the vinyl moiety (entry 4). In this case 5a was a suitable precatalyst. 
Conclusions
A facile system for the derivatisation of unprotected halogenated phenylalanines, tryptophans and dipeptides, containing these amino acids, is described in water or mixed water/iPrOH as solvent. Compared to the previously reported catalytic systems for aqueous media, the PdCl2(dppf) catalyst shows an increased tolerance for a broad range of side chain functionalities, including primary amide and imidazole moieties, without the need for protecting groups. Various (hetero)aromatic boronic acids reagents can be used and lead to molecules which can be used directly as building blocks in peptide synthesis. Interestingly, the PdCl2(dppf) system also enabled access to unprotected vinylated amino acids. 
Experimental Section General
Column chromatography purifications were conducted with silica gel 60 (40-63 µm; Grace Davisil). TLC was carried out on glass plates precoated with silica gel 60F254 (Merck); the spots were visualised under UV light (λ= 254 nm) and/or a KMnO4 (aq.) solution was used to reveal spots. The used HPLC system consisted of Waters 1525 Binary HPLC pumps and a Waters 2487 dual absorbance wavelength detector, with detection set at 215 nm and 254 nm, connected to an auto-sampler. All HPLC analyses were performed on this equipment, unless stated otherwise. Upon use of "system 2", a similar setup, without an autosampler, was used. A Grace Vydac C18 (25 cm x 4.6 mm x 5 m) reversed phase column was employed in both systems. The solvent system consisted of water (with 0.1 % TFA)/acetonitrile (with 0.1 % TFA) mixtures. In general, the samples were dissolved in water/acetonitrile (1:1) and eluted with a standard gradient going from 3 % to 100 % AcN in 20 minutes, and with a flow rate of 1 ml/min. Preparative HPLC was conducted on a Gilson preparative HPLC system mounted with a Supelco Discovery Bio Wide Pore C18 column. 1 H NMR and 13 C NMR spectra were recorded on a Bruker Avance DRX 250 console and a Bruker Avance II 500 console at 250 or 63 MHz and 500 or 126 MHz, respectively. The deuterated solvent is mentioned for each individual spectra. Chemical shifts (δ) are presented in parts per million (ppm), while coupling constants (J) are given in Hertz (Hz). High resolution mass spectrometry was conducted on a Waters Micromass QTof system in ES+ mode, using reserpine as the reference. Reagents were used as purchased from Sigma Aldrich (catalysts and general chemicals), Chemimpex (amino acid derivatives) or ABCR (general chemicals). The halogenated tryptophans were obtained via a biotransformation protocol as described in Smith. D. et al.
[11a] The amino acids all possessed the Lconfiguration. The Suzuki-Miyaura reactions were run in mQ water and, where applicable, HPLC grade iPrOH was used.
Preparation of catalysts
All catalysts, except 1a, 1b and 3, were used as obtained from their respective commercial source. Precatalyst 5b was a kind gift from the ORSY research group, University of Antwerp. For 1a and 1b, the 0.01 M catalyst solution was prepared as described by Davis and coworkers.
Sulfonated SPhos (3) was prepared starting from SPhos as described by Buchwald and coworkers.
[3c] Spectra were consistent with literature data.
[3c] Ligand 3 was obtained as a yellow solid in 82 % yield (102 mg). 
MS (ES+)
:
General procedure for the evaluation of ligands in the Suzuki-Miyaura coupling
To a solution of 6a-c (25 mg, 0.102 mmol), K2CO3 (70.8 mg, 0.510 mmol) and phenylboronic acid (14.9 mg, 0.123 mol) in H2O (2 mL) the respective catalyst (5 mol%, 5.1 µmol) was added. The solution was stirred for the reported reaction time (see Table 1 ) at 80°C in a sealed 10 mL vial. HPLC analysis was performed by taking an aliquot (10 µL) of the reaction mixture and further dilution to 1 mL with a H2O/AcN (1:1) mixture.
Solvent ratio evaluation
A 10 mL microwave vial was charged with 6a (50 mg, 0.205 mmol) or 8a (50 mg, 0.145 mmol), phenylboronic acid (1.2 eq), K2CO3 (5 eq) and 5a (1 mol%), and fitted with a stirring bar. A mixture of H2O and iPrOH was added consecutively (to give a total volume of 4 mL, see Table 2 ). The reaction mixture was heated to 80°C for 24 (6a) or 2 hours (8a). HPLC analysis was performed by taking an aliquot (10 µL) of the reaction mixture and further dilution to 1 mL with a H2O/AcN (1:1) mixture. 1, total 2 mL) . The 10 mL microwave vial was fitted with a stirring bar and closed with a crimp cap. The reaction mixture was heated to 80°C for 4 hours. After cooling to RT, the reaction mixture was concentrated by rotary evaporation. The residue was dissolved in H2O (20 mL) and washed with CH2Cl2 (2x 10 mL). The aqueous phase was concentrated and redissolved in a mixture of H2O and AcN (5:1) and purified by preparative HPLC (gradient 0-60 % AcN in H2O over 20 mins, supplemented with 0.1 % TFA). The obtained solutions were lyophilised to obtain 7a-j (TFA salts) as white powders.
Evaluation of boronic acid scope with PdCl2(dppf)
General procedure A For unprotected substrates, 6a (25 mg, 0.102 mmol) was dissolved together with the respective boronic acid (1.2 eq, 0.123 mmol), K2CO3 (70.8 mg, 0.510 mmol) and PdCl2(dppf) 5a (4.2 mg, 5.1 µmol) in a mixture of H2O and iPrOH (1:
General procedure B
For protected substrates, 8a (688 mg, 2 mmol) was dissolved together with the respective boronic acid (1.2 eq, 2.4 mmol), K2CO3 (1.382 g, 10 mmol) and 5a (16.5 mg, 0.02 mmol) in a mixture of H2O and iPrOH (19:1, total 20 mL) in a 50 mL flask, equipped with a stirring bar and a reflux condenser. The reaction mixture was heated to 80°C for 60 mins. After cooling to RT, iPrOH was removed by rotary evaporation and carefully acidified with 5 N HCl to pH= 3, as indicated by pH paper. The aqueous phase was extracted with CH2Cl2 (4x 25 mL). The combined organic layers were dried over MgSO4 and concentrated by evaporation. The crude was purified by column chromatography with a mixture of ethyl acetate and petroleum ether, supplemented with 2 % of acetic acid. The combined fractions were concentrated under high vacuum and lyophilised to obtain 9a-j as white solids to yellow solids.
Preparation of H-Phe(4-phenyl)-OH (7a)
Compound 7a was prepared via general procedure A to give a white powder in 48 % yield (16.6 mg 
Preparation of H-Phe(3-phenyl)-OH (7b)
Compound 7b was prepared according to general procedure A and obtained as a white powder in 41 % yield (14. 
Preparation of H-Phe(2-phenyl)-OH (7c)
Compound 7c was prepared according to general procedure A as a white powder in 38 % yield (13.0 mg 
Preparation of H-Phe(4-p-trifluoromethylphenyl)-OH (7e)
Compound 7e was prepared according to general procedure A as a white powder in 45
Preparation of H-Phe(4-indol-5-yl)-OH (7g)
Compound 7g was prepared according to general procedure A as a white powder in 37 % yield (14.5 mg). HPLC: tR = 11.7 min; HRMS: [M+H] + calculated 281.1285 found 281.1288; 
Preparation of H-Phe(4-furan-3-yl)-OH (7h)
Compound 7h was prepared according to general procedure A as a white powder in 33 % yield (11.0 mg). HPLC: tR = 11.0 min; HRMS: [ 
Preparation of H-Phe(4-thien-3-yl)-OH (7i)
Compound 7i was prepared according to general procedure A as a white powder in 39 % yield (13.7 mg). HPLC: tR = 11.9 min; HRMS: [ 
Preparation of H-Phe(4-vinyl)-OH (7j)
Compound 7j was prepared according to general procedure A from 10a ( 
Preparation of Boc-Phe(4-phenyl)-OH (9a)
Compound 9a was prepared according to general procedure B as a white solid in 83 % yield (565 mg). The crude was purified with silica column chromatography with petroleumether/EtOAc 2:1 + 2 % AcOH. 
Preparation of Boc-Phe(4-p-methoxyphenyl)-OH (9b)
Compound 9b was prepared according to general procedure B as a white solid in 88 % yield (652 mg). The crude was purified with silica column chromatography with petroleumether/EtOAc 3:1 + 2 % AcOH). Rf: 0. 30 
Preparation of Boc-Phe(4-p-trifluoromethylphenyl)-OH (9c)
Compound 9c was prepared according to general procedure B as a white solid 79 % yield (644 mg). The crude was purified with silica column chromatography with petroleumether/EtOAc 4:1 +2 % AcOH 
Preparation of Boc-Phe(4-o-tolyl)-OH (9d)
Compound 9d was prepared according to general procedure B as a white powder in 85 % yield (603 mg). The crude was purified with silica column chromatography with petroleumether/EtOAc 4:1 + 2 % AcOH 
Preparation of Boc-Phe(4-indol-5-yl)-OH (9e)
Compound 9e was prepared according to general procedure B as a white powder in 89 % yield (676 mg). The crude was purified with silica column chromatography with petroleumether/EtOAc 2:1 +2 % AcOH 
Preparation of Boc-Phe(4-furan-3-yl)-OH (9f)
Compound 9f was prepared according to general procedure B as a white powder in 84 % yield (557 mg). The crude was purified with silica column chromatography with petroleumether/EtOAc 1:1 + 2 % AcOH 
Preparation of Boc-Phe(4-thien-3-yl)-OH (9g)
Compound 9g was prepared according to general procedure B as a white powder in 89 % yield (618 mg). The crude was purified with silica column chromatography with petroleumether/EtOAc 2:1 + 2 % AcOH). Rf: 0.39 (p.e./EtOAc 1:1 + 2 % AcOH); HPLC: tR = 17.1 min; HRMS: [M+Na] + calculated 370.1083 found 370.1070; 
Preparation of Boc-Phe(4-vinyl)-OH (9h)
Compound 11a was dissolved (782 mg, 2 mmol) together with potassium vinyltrifluoroborate (321 mg, 2.4 mmol), K2CO3 (1.382 mg, 10 mmol) and 5a (16.5 mg, 0.02 mmol) in a mixture of H2O and iPrOH (1:1, total 20 mL). The solution was heated to 80°C for 1 hour. Work-up was similar as described in general procedure B. The crude was purified by silica column chromatography (CH2Cl2/MeOH/AcOH 97:1:2) and lyophilised. 9h was obtained as a yellow solid in 81 % yield (471 mg 
Preparation of Boc-Phe(3-vinyl)-OH (9i)
Compound 9i was prepared starting from 11b following the procedure as described for 9h. After column chromatography, the product was obtained as a white solid in 89 % yield (520 mg). Rf: 0.22 (CH2Cl2/MeOH/AcOH 97:1:2); HPLC: tR = 16.9 min; HRMS: [ 
Preparation of Boc-Phe(2-vinyl)-OH (9j)
Compound 9j was prepared starting from 11c following the procedure as described for 9h. After column chromatography, the product was obtained as a white solid in 89 % yield (517 mg). Rf: 0. Dipeptide carboxylic acids were synthesised on 2-Cl-tritylchloride resin (obtained from GL Biochem or Chemimpex) following standard Fmocbased solid-phase peptide synthesis (SPPS) in a polypropylene syringe with polyethylene frit using SPPS grade CH2Cl2 or DMF. The protocol was started by swelling the resin in DMF for 30 mins and followed by coupling the first amino acid (Fmoc-4-Br-Phe, 2 eq) with DIPEA (4 eq) in DMF for 90 mins. Reagents were filtered and the resin was washed with DMF, iPrOH and CH2Cl2 (each 3x 1 min). The resin was treated with a mixture of MeOH, CH2Cl2 and DIPEA (2:17:1) for endcapping (4x 5 min). After washing, the Fmoc protecting group was removed by treating the resin with 20 % 4-methylpiperidine in DMF (5 min, 15 min). After washing, the second amino acid (either as Boc-AA-OH or Fmoc-AA(Pg)-OH was coupled (3 eq) with HCTU (3 eq) in 0.4 M NMM for 60 mins. The excess reagents were removed by filtration and the resin was washed. The Kaiser ninhydrin test was used to check for complete conversion. If complete coupling was observed, the resin was treated with 20 % 4-methylpiperidine in DMF (in the case Boc-AA-OH was coupled, this deprotection step was not necessary) for 5 mins and 15 mins. Upon completion of the peptide assembly, the resin was washed and treated with a standard cleavage cocktail (95 % TFA and 5 % H2O) 1 for 2 hours.
2
The deprotected peptide was collected by filtration, concentrated in vacuo and purified over a C-18 cartridge (Supelco) while eluting with H2O/AcN (5:1). Afterwards, the dipeptides were lyophilised and obtained as white to off-white powders, identification and purity were determined by HPLC and LC/MS analysis. As such, the dipeptides were prepared as their corresponding TFA salts. [a] Measured by HPLC system 2 (215 nm).
Suzuki-Miyaura derivatisation of dipeptides 12a-12m
In a 10 mL vial, dipeptide bromide (12a-12m, 0.063 mmol) was dissolved in H2O (1.7 mL) together with phenylboronic acid (19.1 mg, 0.157 mmol), K2CO3 (43.4 mg, 0.312 mmol or 52.1 mg, 0.374 mmol for entries 6, 12 and 13). The vial was fitted with a stirring bar and the 0.01 M 1a solution (315 µL, 3.15 µmol) was added with a syringe. The reaction mixture was heated to 80°C. Reaction follow-up was performed by HPLC analysis at 215 nm. For this analysis, 10 µL aliquot of the reaction mixture was diluted to 1 mL with H2O/AcN (1:1). Conversion was calculated based on the area under the curve (at 215 nm) by comparison of starting product and cross-coupled product peak surface area. LC/MS analysis was performed on the crude mixtures to identify the cross-coupled products. Compound 6a (2.44 g, 10 mmol) was dissolved in MeOH (20 mL, HPLC grade) in a 50 mL flask, equipped with a stirring bar. The reaction mixture was cooled to 0°C by means of water/ice bath and distilled SOCl2 (2.5 eq, 1.82 mL, 25 mmol) was added dropwise. After complete addition, the water/ice bath was removed and the flask was equipped with a reflux condenser and heated to 45°C for overnight reaction. Conversion was checked by HPLC and the reaction mixture was concentrated by rotary evaporation. The pale yellow solid was washed thoroughly with cold diethylether and dried overnight with a high vacuum pump. H-Phe ( Spectra for HCl.H-Phe(4-Br)-OMe were consistent with literature data. [29] To a solution of HCl.H-Phe(4-Br)-OMe (1.5 g, 5.09 mmol), Boc-Asn-OH (1.42 g, 6.11 mmol) and HOBt (1.25 g, 8.15 mmol) in CH2Cl2 (20 mL, SPPS grade) was added DIPEA (2.66 mL, 15.28 mmol). The reaction mixture was cooled with a water/ice bath to 0°C and a solution of EDC.HCl (1.56 g, 8.15 mmol) in CH2Cl2 (5 mL, SPPS grade) was added dropwise. After complete addition, the reaction mixture was allowed to warm to room temperature and stirred for 16 h. The obtained cloudy solution was diluted with CH2Cl2 (25 mL) and filtered over a glass frit. The organic phase was washed with saturated NH4Cl (2x 25 mL), aq. sat. NaHCO3 (2x 25 mL), water (2x 25 mL) and brine (1x 25 mL). The solution was dried over MgSO4 and concentrated by evaporation. The crude was suspended in a minimal amount of methanol and filtered over a glass frit. After drying overnight with a high vacuum pump, 14a was obtained as a white solid in 65 % yield (1.65 g). HPLC: tR = 14. 
Preparation of Boc-Asn-Phe(4-Br)-OH (14b)
Compound 14a (150 mg, 0.318 mmol) was dissolved in a mixture of THF/H2O (total 2 mL, 7:1) in a 10 mL flask. To this solution was added LiOH monohydrate (93 mg, 2.223 mmol) and formic acid (17 µL, 0.445 mmol). The reaction mixture was stirred for 16 hours. After complete conversion of starting material, the reaction mixture was concentrated by evaporation and resuspended in H2O (10 mL). The aqueous phase was washed with CH2Cl2 (2x 5 mL) and was acidified with 1 N HCl to pH = 3, as indicated by pH paper. The aqueous layer was extracted with CH2Cl2 (4x 10 mL) and the combined organic layers were collected and washed with brine (1x 20 mL) and dried over MgSO4. The product was concentrated by evaporation and dissolved in water with a minimal amount of AcN. After lyophilisation, 14b was obtained as a white powder in 74 % yield (107 mg). HPLC: tR = 13. 
Suzuki-Miyaura derivatisation of Asn-Phe dipeptides (14a,b and 12j, n): General procedure C
In a 10 mL MW vial, the dipeptide bromide (0.055 mmol) was dissolved together with phenylboronic acid (16.6 mg, 0.136 mmol) and K2CO3 (37.7 mg, 0.273 mmol or 45.6 mg, 0.330 mmol for 12j, n) in a mixture of H2O and iPrOH (1:1, total 2 mL). Formic acid (2 µL, 0.055 mmol) was added to the reaction mixture. The catalyst was added in the respective amount (5 mol% to 100 mol%, see Table 5 ). The vial was equipped with a stirring bar, closed with a crimp cap and heated to 80°C. Conversion of the reaction was monitored by HPLC (215 nm). If satisfactory conversion was obtained (only with 5a), the reaction mixture was allowed to cool to room temperature, concentrated and redissolved in 5 mL of H2O.
Preparation of Boc-Asn-Phe(4-phenyl)-OMe (17a)
Derivatisation of 14a (26 mg, 0.055 mmol) was performed as described in general procedure C. The aqueous phase was extracted with CH2Cl2 (3x 5 mL). The combined organic layers were combined and dried over MgSO4. The reaction mixture was concentrated by evaporation and resuspended in H2O with a minimal amount of AcN (total 4 mL). The product was purified by prep HPLC and obtained as a white powder after lyophilisation. Concomitant hydrolysis to 14b was observed by LC/MS analysis. Further characterisation indicated that the product was hydrolysed.
Preparation of Boc-Asn-Phe(4-Phenyl)-OH (17b)
Derivatisation of 14b (25 mg, 0.055 mmol) was performed as described in general procedure C using 5a (5 mol%, 2.3 mg, 2,75 µmol). After redissolving the crude in H2O, the mixture was acidified with 1N HCl to pH= 3, as indicated by pH paper and extracted with CH2Cl2 (3x 5 mL). The combined organic layers were dried over MgSO4, concentrated by evaporation and redissolved in in H2O with a minimal amount of AcN (total 4 mL). The product 17b was purified by prep HPLC and obtained as a white powder after lyophilisation in 66 % yield (16.6 mg). HPLC: tR = 15.0 min; HRMS: [M+Na] + calculated 478.1949 found 478.1942.
Preparation of H-Asn-Phe(4-phenyl)-OH (13j)
Derivatisation of 12j (25 mg, 0.055 mmol), prepared by Fmoc-based SPPS (vide supra), was performed as described in general procedure C using 5a (5 mol%, 2.3 mg, 2,75 µmol). The obtained aqueous phase was washed with CH2Cl2 (1x 5 mL), concentrated by rotary evaporation and resuspended in H2O with a minimal amount of AcN (total 4 mL). The crude was purified by prep HPLC and lyophilised to obtain 13j as a white powder in 32 % yield (7.9 mg 
Preparation of H-Gln-Phe(4-phenyl)-OH (13n)
Derivatisation of 12n (26 mg, 0.055 mmol), prepared by Fmoc-based SPPS (vide supra), was performed as described in general procedure C using 5a (5 mol%, 2.3 mg, 2,75 µmol). Isolation of 13n was performed as described for 13j The crude was purified by prep HPLC and lyophilised to obtain 12n as a white powder in 36 % yield (9.3 mg 
Preparation of Boc-His(BOM)-Phe(4-Br)-OH (18b)
Compound 18b (200 mg, 0.373 mmol) was prepared starting from 18a according to a similar procedure as described for 13b with LiOH monohydrate (78 mg, 1.864 mmol) in THF/H2O (7:1; total 2 mL). After lyophilisation, a white powder was obtained in 68 % (133 mg 
Preparation of H-His(BOM)-Phe(4-Br)-OH (18c)
To a solution of 15c (54 mg, 0.090 mmol) in CH2Cl2 (4 mL) was added trifluoroacetic acid (1 mL). The reaction mixture was stirred for 2 hours and concentrated by evaporation. After lyophilisation of the product, a white powder was obtained in quantitative yield (53.7 mg) as the trifluoroacetic acid salt. HPLC: tR = 11. 
Preparation of 19a-d
Histidine-containing dipeptides (19a-b) and tripeptides (19c-d) were prepared by standard Fmoc-based SPPS (vide supra). Acylation of the C-terminus (19b and 19d) was performed by treating the resin with a mixture of acetic anhydride (10 eq) and DIPEA (20 eq) in DMF (3 mL) for 30 mins. Kaiser ninhydrin test was performed to confirm complete acylation of the peptide. Afterwards, the resin was washed consecutively with DMF, iPrOH and CH2Cl2 (each 3x 1 min). For final cleavage, the resin was treated with a cleavage cocktail (3 mL), consisting of TFA (95 %), H2O (2.5 %) and triethylsilane (2.5 %) for 2 hours. The obtained crude peptides were purified by preparative HPLC and obtained as white powders after lyophilisation. 
Suzuki-Miyaura derivatisation of His-Phe dipeptides (18a-d, 19a-b) and tripeptides (19c-d): General procedure D
In a 10 mL MW vial, the dipeptide halide (0.02 mmol-0.042 mmol) was dissolved together with phenylboronic acid (2.5 eq) and K2CO3 (5-6 eq) in a mixture of H2O and iPrOH (1:1, total 2 mL). The catalyst was added in the respective amount (5 mol% to 100 mol%, see Table 6 ). Conversion of the reaction was monitored by HPLC (215 nm). The vial was fitted with a stirring bar, closed with a crimp cap and heated to 80°C for the respective time. Conversion of the reaction was monitored by HPLC (215 nm). If satisfactory conversion was obtained (only with catalyst 5a), the reaction mixture was allowed to cool to room temperature, concentrated and redissolved in 5 mL of H2O.
Preparation of Boc-His(BOM)-Phe(4-phenyl)-OMe (20a)
Derivatisation of 18a (25 mg, 0.041 mmol) was performed according to general procedure D with 5a (5 mol%, 1.7 mg, 2.03 µmol) and K2CO3 (28.1 mg, 0.203 mmol) for 2 hours. Isolation of the product was similar to the purification of 14a, correspondingly, hydrolysis to 20b was observed by LC/MS and 1 H-NMR analysis, consistent with data found for 20b.
Preparation of Boc-His(BOM)-Phe(4-phenyl)-OH (20b)
Derivatisation of 18b (25 mg, 0.042 mmol) was performed according to general procedure D with 5a (5 mol%, 1.7 mg, 2.08 µmol) and K2CO3 (28.7 mg, 0.208 mmol) for 2 hours. The purification was performed as described for 14b. After preparative HPLC and lyophilisation, 20b was obtained as a pale brown powder in 56 % yield (14.0 mg). HPLC: tR = 15.9 min; HRMS: [M+H] + calculated 599.2864 found 599.2869.
Preparation of H-His(BOM)-Phe(4-phenyl)-OH (20c)
Derivatisation of 18c (25 mg, 0.042 mmol) was performed according to general procedure D with 5a (5 mol%, 1.7 mg, 2.09 µmol) and K2CO3 (34.6 mg, 0.251 mmol) for 2 hours. Isolation of 20c was performed as described for 12j. 
Preparation of Ac-Gly-His-Phe(4-phenyl)-OH (20g)
Derivatisation of 19d (12.5 mg, 0.020 mmol) was performed according to general procedure D with phenylboronic acid (6.1 mg, 0.050 mmol), 5a (5 mol%, 0.8 mg, 1.00 µmol) and K2CO3 (13.8 mg, 0.120 mmol) in 1 mL of a mixture of H2O and iPrOH (1:1). Isolation of 20g was performed as described for 12j. After purification by preparative HPLC and lyophilisation, the product was obtained as a white powder in 29 % yield 
Preparation of H-Met-Glu-His-Phe(4-phenyl)-Arg-Trp-Gly-OH (22)
The heptapide 21 (10.0 mg, 7.3 µmol) was dissolved with phenylboronic acid (2.2 mg, 0.018 mmol), K2CO3 (7.0 mg, 0.051 mmol) and 5a (5 mol%, 0.3 mg, 0.36 µmol) in a mixture of H2O and iPrOH (1:1, total 1 mL) in a microwave vial (10 mL). The vial was equipped with a stirring bar and sealed with a crimp cap. The mixture was heated to 80°C with an oil bath for 2 hours. The mixture was allowed to cool to room temperature and concentrated by evaporation. The crude was redissolved in H2O, with a minimal amount of AcN, and purified by preparative HPLC to yield 22 as a white powder in 18 % yield (1.7 mg). HPLC: tR = 12.4 min; HRMS:
[M+H] + calculated 1038.4614 found 1038.4651. 
Preparation of 5-phenyltryptophan (28a)
Preparation of H-Gly-Trp(5-phenyl)-OH (29a)
Compound 27a (25 mg, 0.066 mmol) was dissolved with phenylboronic acid (20.2 mg, 0.166 mmol) and K2CO3 (45.9 mg, 0.332 mmol) in 1.7 mL H2O. To this was added 0.01 M 1a solution (332 µL, 3.32 µmol). The reaction mixture was stirred for 2h at 80°C. The reaction mixture was cooled to room temperature and concentrated by evaporation. The crude was redissolved in H2O with a minimal amount of AcN and purified by preparative HPLC. After lyophilisation, 29a was obtained as a white powder in 33 % yield (9.6 mg). HPLC: tR = 13.8 min; HRMS: [M+H] + calculated 338.1499 found 338.1504.
Preparation of H-Phe-Trp(5-phenyl)-OH (29b)
Compound 29b was prepared starting from 27b (25 mg, 0.054 mmol) following the procedure as described for 29a. The product was obtained as a white powder after lyophilisation in 24 % yield (5.9 mg). HPLC: tR = 13.8 min; HRMS: [M+H] + calculated 428.1969 found 428.1963.
Preparation of H-Lys-Trp(5-phenyl)-OH (29c)
Compound 29c was prepared starting from 27c (25 mg, 0.052 mmol) following the procedure as described for 29a. The product was obtained as a white powder after lyophilisation in 29 % yield (8.9 mg). HPLC: tR = 11.9 min; HRMS: [M+H] + calculated 409.2234 found 409.2206.
Preparation of 6-phenyltryptophan (28b)
Compound 28b was prepared starting from 26b according to the procedure described for 28a. 
Preparation of 7-phenyltryptophan (28c)
Compound 28c was prepared starting from 26c according to the procedure described for 28a. The product was obtained as a white powder after preparative HPLC in 44 % yield. (12.9 mg Spectra were consistent with literature data.
[5a]
Preparation of 7-vinyltryptophan (31)
Compound 31 was prepared by dissolving 30 (29 mg, 0.078 mmol), potassium vinyltrifluoroborate (26 mg, 0.195 mmol), K2CO3 (54 mg, 0.390 mmol) and 5a (5 mol%, 3.2 mg, 3.90 µmol) in a mixture of H2O and iPrOH (1:1, total 2 mL). The reaction mixture was stirred for 2 hours at 80°C, allowed to cool to room temperature. The aqueous phase was washed with CH2Cl2 (2x 5 mL) and was acidified with 1N HCl to pH = 3, as indicated by pH paper. The aqueous layer was extracted with CH2Cl2 (4x 10 mL) and the combined organic layers were collected and washed with brine (1x 20 mL) and dried over MgSO4. The product was concentrated by evaporation and dissolved in water with a minimal amount of AcN. The crude was purified by preparative HPLC and obtained as a white powder after lyophilisation in 51 % yield (13.0 mg). HPLC: tR = 11.1 min; HRMS: [ MW: microwave; pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; Pg: protecting group; SAR: structure-activity relationships; sulfonated SPhos: sodium 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl-3'-sulfonate; SPPS: solidphase peptide synthesis; TES: triethylsilane; TFA: trifluoroacetic acid; TPPTS: 3,3′,3″-phosphanetriyltris(benzene sulfonic acid).
